SOURCE: Cardima, Inc.

March 04, 2008 08:45 ET

Cardima Announces Appointment of Dr. Abraham G. Kocheril to Scientific Advisory Board

FREMONT, CA--(Marketwire - March 4, 2008) - Cardima, Inc. (OTCBB: CADM) announced the appointment of Dr. Abraham G. Kocheril to its Scientific Advisory Board. Dr. Kocheril is a trained Cardiologist and ABIM certified Clinical Cardiac Electrophysiologist.

Dr. Kocheril is currently a Professor of Medicine, Director of Clinical Electrophysiology at the University of Illinois at Chicago. Prior to his current appointment, he was the Head of Cardiac Electrophysiology, Carle Heart Center, Urbana, Illinois. Dr. Kocheril did his postgraduate training in Cardiology and Electrophysiology at Yale University School of Medicine, New Haven, CT and Brown University, Providence, RI.

In addition to authoring many publications, Dr. Kocheril is also an official reviewer for numerous prestigious journals, including: American Journal of Cardiology, Pacing and Clinical Electrophysiology (PACE), and Heart (British Medical Journal). He also serves on the editorial board of EP Lab Digest.

Dr. Kocheril has worked extensively with Cardima's EP ablation and diagnostic products and has published papers on this work. Additionally he has participated in numerous trials and research studies for industry, the NIH and academic institutions. Dr. Kocheril will consult and advise on Cardima's up-coming clinical studies to support FDA approval to market the EP ablation catheter system for the treatment of Atrial Fibrillation ("AF").

Cardima's CEO, Mr. Cheney, commented on Dr. Kocheril's appointment, "It is a great compliment to Cardima's team of professionals that a physician of Dr. Kocheril's growing worldwide reputation for excellence in research and clinical practice has agreed to work with us. Dr. Kocheril brings a wealth of experience and expertise that will prove invaluable as we move forward with our clinical studies. Dr. Kocheril played a key role in helping Cardima develop and improve its EP products. He will now play an even more important and direct role as an advisor to the board of directors as Cardima moves forward towards FDA regulatory approval and worldwide commercialization of our products."

The entire Board of Directors welcomes Dr. Kocheril's appointment.

About Cardima

Cardima, Inc. has developed the PATHFINDER® and REVELATION® Series of diagnostic catheters, the INTELLITEMP® Energy Management Device, and the Surgical Ablation System (SAS). All of these devices are CE marked and received U.S. FDA 510(k) clearance. The REVELATION® Series of ablation catheters with the INTELLITEMP® EP Energy Management Device was developed and marketed for the treatment of atrial fibrillation ("AF") after receiving CE mark approval in Europe; it is not currently available in the U.S.

For more information, please visit the Company's website at

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by such forward-looking statements. Potential risks and uncertainties include: the uncertainties associated with the prospects for FDA approval of any new devices; the prospect for any future clinical trials or regulatory activities; the risk that the Company will not be able to raise additional capital in the immediate term as needed to continue operations and the risk that we will be unable to secure a strategic transaction involving the Surgical Ablation System. Additional risks and uncertainties are set forth in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, the Company's Quarterly Report on Form 10-QSB for the third quarter ended September 30, 2007, and in the Company's subsequent SEC filings. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Contact Information